POWER IN NUMBERS: REVISITING EFFICACY & SAFETY OF NOACS IN AF

Where Do We Stand With NOACs in AF 6 Years Later?

Danish Registry for AF – Larsen Analysis: Similar Ischemic Stroke Rates

Danish Registry for AF – Larsen Analysis: Any Bleeding

Danish Registry for AF – Larsen Analysis: Mortality

Danish Registry for AF -- Staerk Analysis: Decreased Ischemic Stroke Rates

Danish Registry for AF -- Staerk Analysis: Intracranial Bleeding Rates

Danish Registry for AF -- Larsen Analysis: What Did We Learn?

First Medicare Analysis: CV, Bleeding, and Mortality Risks in Elderly Medicare Patients Treated With Dabigatran or Warfarin for NVAF

Second Medicare Analysis: Dabigatran and Rivaroxaban -- Demographics

Second Medicare Analysis: Dabigatran and Rivaroxaban -- ICH

Second Medicare Analysis: Dabigatran vs. Rivaroxaban -- Mortality

Danish Registry for AF -- Gorst-Rasmussen Data: Bleeding With Different Doses of Rivaroxaban and Dabigatran

Benefit of Comparison With Observational Data

Idarucizumab: A Specific Reversal Agent for Anticoagulant Activity of Dabigatran

RE-VERSE AD™: Primary Endpoint in Group A & B With Idarucizumab -- dTT and ECT

RE-VERSE AD: Study Update

RE-VERSE AD: Multicenter, Ongoing, Open-label, Single-arm Phase 3-S

RE-VERSE AD: Selected Secondary Endpoints

RE-VERSE AD: Updated Patient Demographics

RE-VERSE AD -- Group A: Updated Site of Index Bleed

RE-VERSE AD -- Group B: Updated Indications for Surgery/Procedures

RE-VERSE AD: Updated Primary Results

RE-VERSE AD -- Group A: Updated Local Confirmation of Hemostasis

RE-VERSE AD -- Group B: Updated Periprocedural Hemostasis

RE-VERSE AD -- Updated Adjudicated Post-Reversal Thromboembolic Events Through 90 Days

RE-VERSE AD: Updated Reinitiation of Antithrombotic Treatment within 90 days

RE-VERSE AD: Updated Mortality (Kaplan-Meier Survival)

RE-VERSE AD: Updated Conclusions

RE-VERSE AD: Patients Treated With More Than One 5 g Dose of Idarucizumab -- Updated Analysis

Andexanet: Reversal of Factor Xa Inhibitor Activity

ANNEXA- Phase 3: Andexanet Reverses the Effects of Factor Xa Inhibitors

ANNEXA-4: Phase 4 Study With Andexanet

Comparison of Features of Idarucizumab and Andexanet

Ciraparantag

What Affects Choice of Anticoagulant?

Abbreviations

Abbreviations (cont)